Clinical Trials Logo
  1. Home
  2. Hepatic Insufficiency
  3. NCT01891526
  4. Details
NCT01891526 Clinical Trial

Single Dose of 9-cis-retinoic Acid in Hepatic Patients

Hepatic Insufficiency Clinical Trial

Official title:
The Pharmacokinetics of a Single Dose of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Moderate to Severe Hepatic Insufficiency

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01891526
Other study ID # 2010-338
Secondary ID Allitretinoin
Status Completed
Phase N/A
First received June 21, 2013
Last updated June 28, 2013
Start date December 2010
Est. completion date June 2012

Study information
Verified date June 2013
Source University Hospital, Gentofte, Copenhagen
Contact n/a
Is FDA regulated No
Health authority The Danish National Committee on Biomedical Research Ethics, Denmark:United States: Food and Drug Administration
Study type Observational

Clinical Trial Summary

To test whether patients with hepatic insufficiency can tolerate one oral dose of 9-cis-retinoic acid and to test whether the metabolism of retinoic acid is altered.

Recruitment information / eligibility
Status Completed
Enrollment 20
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Have biopsy verified hepatic insufficiency

2. Medically stable.

3. Ultra sonic examination of lever within the past 3 months

4. No pregnancy documented in women. use of anticonception during study and 1 month after

Exclusion criteria:

1. Odd blood counts and samples not related to hepatic disease

2. encephalopathy (> grad II)

3. concomitant treatment with pharmaca that is metabolized by CYP3A4 in the liver.

4. Cardiac disease

5. Kidney disease

6. Epilepsia

7. Stroke

8. Esophagal bleeding

9. Severe ascites

10. HIV-positivity

11. Psychiatric disorder

12. Cancer

13. pregnancy or lactating women.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Drug:
• 9-cis-retinoic acid
Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure

Locations
Country Name City State
Denmark Gentofte Hospital Gentofte

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Gentofte, Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome
Type Measure Description Time frame Safety issue
Primary A comparison of the metabolisation of retinoic acid in patients with hepatic insufficiency and controls Analysis on samples 24 hours No
See also
  Status Clinical Trial Phase
Completed NCT04097704 - Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort
Completed NCT02161224 - A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function Phase 1
Completed NCT00929032 - Liver Transplantation and Reticuloendothelial Clearance Capacity N/A
Completed NCT00509210 - Study of Telaprevir in Subjects With Hepatic Impairment Phase 1
Completed NCT02894385 - Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201) Phase 1
Completed NCT03306667 - Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency) Phase 1
Completed NCT04867941 - A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196 Phase 1
Terminated NCT02457702 - Mitochondrial Function in Patients With Severe Liver Disease N/A
Completed NCT02090621 - Extracorporeal Photopheresis After Liver Transplant Phase 2
Completed NCT02249442 - Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency Phase 1
Completed NCT03341884 - A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants Phase 1
Completed NCT01475136 - A Study of LY2140023 in Hepatically-Impaired Participants Phase 1
Completed NCT00969813 - A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function Phase 1
Completed NCT00968591 - Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency Phase 1
Completed NCT00931060 - Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects N/A
Completed NCT00416702 - Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function Phase 1
Completed NCT03968848 - Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite Phase 1
Completed NCT00692341 - Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics Phase 1
Completed NCT00314054 - Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults Phase 1
Completed NCT05731895 - A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems Phase 1